CA2228054A1 - Lubeluzole n-oxide - Google Patents
Lubeluzole n-oxide Download PDFInfo
- Publication number
- CA2228054A1 CA2228054A1 CA002228054A CA2228054A CA2228054A1 CA 2228054 A1 CA2228054 A1 CA 2228054A1 CA 002228054 A CA002228054 A CA 002228054A CA 2228054 A CA2228054 A CA 2228054A CA 2228054 A1 CA2228054 A1 CA 2228054A1
- Authority
- CA
- Canada
- Prior art keywords
- oxide
- lubeluzole
- solution
- composition according
- neuroprotectant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention is concerned with lubeluzole N-oxide(s), compositions containing the N-oxide(s), methods of preparing these and their use as a medicine, in particular in the treatment of conditions involving cerebral hypoxia.
Description
CA 022280~4 1998-01-27 2 PCTAEP~ C~
LUBELUZOLE N-OXIDE
s The present invention is concerned with neUI- pl(~te~ t N-oxide forms of lubeluzole, compositions cont~inin~ such N-oxide~s), methods of ~ alillg these and their use as a m.orlirinlo., in particular in the tre~tm~nt of conditions involving cerebral hypoxia.
In US~,861,785 there are described benzoxazol- and b~llzollliazolamine deli~ s having anti-hypoxic and anti-anoxic activity. In W0-92/14,73 1 some of these b~.lzotlliazolamine del;v~ti~es were disclosed having useful anti-stroke activity.
Injectable formulations of (S)~-[(2-benzothiazolyl) methylamino]-a-[(3,4-dinuol(J-phenoxy)methyl~-l-piperidine-ethan~l (generically known as lubeluzole) are disclosed in Eulope~- Patent application No. 94203422.4 filed 24 November 1994.
Conditions involving cerebral hypoxia con~lise stroke, more in particular icchaemic stroke, intracerebral h~PInorrh~e and subarachnoid haemorrhage, and head trauma.The l,e~.l.. nt of conditions involving cerebral hypoxia ~_ùl~ tly consists mainly of ne.~u~-ul~,clive and of haematologic therapeutic strategies. Optimal therapies remain 20 to be de terminP(l Such an optimized therapy for the tre~tm~nt of hypoxia is the subject of the present invention. In particular, it concerns providing an N-oxide of lubeluzole, a pharm~elltir~lly acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof, as a new medicine for the treatment of conditions involving cerebral hypoxia. The product is suitable for intravenous and intraderrnal 25 ~timinictration by infusion which is the most a~ u~.iate route of ~tlmini~tration for hypoxic patients, and also orally, which route is most suitable for m~int-on~ e therapy.
E~.p~.; . . .~ nt~ with the cis N-oxide form of lubeluzole in an animal model test of acute stroke in~ic~te that it has superior neuloproLeCtant activity over the compound lubeluzole.
The N-oxides of lubeluzole are meant to comprise those compounds wherein one or more of the nitrogen atoms are oxidized, in particular those wherein the piperidine nitrogen is oxidized.
3s More in particular, the present invention is concerned with lubeluzole N-oxide, the cis and trans forms of which are represented by the following formulae:
~ . , CA 022280~4 1998-01-27 W O 97/15572 PCT~EP96/04608 O~ 1~- ~ N ~ Icis,(S)]
OH
~ ~~~ ~ ~N ~ [~ans,(S)l Phann~ eut~ ly acceptable acid addition salts comprise the thel~eulically active, non-toxic salt forms obtained by treating a base form with an acid such as, for example, s an inorganic acid, e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric acid; or an organic acid, e.g. acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric, tartaric, citric, meth~n~sulfonic, ethanesulfonic, ben7erlesll1fonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic acid.
Solvates of lubeluzole N-oxide are, for example hydrates, alcoholates.
The cis-oriented N-oxide of lubeluzole is particularly ~l~rcl.~d, and the most preferred form thereof is the hemihydrate, i.e. (-)-[cis] lubeluzole N-oxide hemihydrate.
The N-oxide(s) of lubeluzole can be prepared following art-known procedures of 5 preparing oxides of nitrogen-cont~ining products. They are conveniently prepared by dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant. Examples of such oxidants are hydrogen peroxide, peroxic acids, e.g.
m-chlor~,.benzoic acid, metal oxides, e.g. NaWO4 and the like. Suitable solventsare, for example, water and halogenated hydrocarbons, in particular dichloromethane.
Hereinafter, the amounts of each of the ingredients in liquid compositions are expressed as percentages by weight based on the total volume of the formulation,unless otherwise indicated. Amounts in solid preparations are expressed as percentages by weight based on the total weight of the forrnulation, unless otherwise indicated.
Pharmaceutical compositions of lubeluzole N-oxide suitable as medicaments according to the present invention comprise a pharmaceutically effective amount of active ingredient and one or more pharmaceutically acceptable excipients or carriers as known in the art. The pharmaceutical compositions are adapted for oral or parenteral -_ WO 97/15572 PCT/EI~C/O 1603 (including i~ cular, subcutaneous, intrade~mal and intravenous) ~lmini~tration.
The formulations are most conveniently presented in discrete dosage units. Generally, the pharmaceutically acceptable carrier for forrn~ tin~ the neuroprotectant lubeluzole N-oxide as an infusion is an aqueous solution (a) comprising water; an isotonizing 5 agent; and acid, base or buffer substances sufflcient to adjust the pH of the solution in the range of from 2.5 to 3.6.
In particular, the concentration of lubeluzole N-oxide in the present solutions (a) may range from 0.005% to 5%, ~lefe~ably from 0-01% to 1%, more preferably from 0.02%o to 0.2% and in particular is about 0.0~%.
Further, the present solutions (a) conveniently comprise from 1 to 10% isotonizing agent. The use of glucose as isotonizing agent has the advantage that very clearsolutions are obtained. Preferably, glucose is used in a concentration from 2 to 10%, 15 most preferably of about 5%.
The solutions (a) further comprise acid and base ~ubsl~lces to ~.A;nl~;n the pH of the solution in the range from 2.5 to 3.6, preferably in the range from 3.0 to 3.4, most preferably at about 3.2. Preferably, the pH of the solutions (a) is adjusted by 20 a~l~liate amounts of hydrochloric acid and sodium hydroxide. The pH may also be adjusted by buffer systems comprising mixtures o~ a~ riate amounts of an acid such as phosphoric, tartaric or citric acid, and a base, in particular sodium hydroxide.
In order to increase the solubility of lubeluzole N-oxide in the present formulations, a 25 solubilizer may be used. Conveniently, a cyclodextrin (CD) or a derivative thereof may be used. Appropriate cyclodextrin derivatives are a-, 13-. ~y-cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups o~ the anhydroglucose units of the cyclodextrin are substituted with Cl 6alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated ¦3-cyclodextrin; hydroxy-30 C1 6alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxy-butyl; carboxy-C1 6alkyl, particularly carboxymethyl or carboxyethyl; C1 6alkyl-carbonyl~
particularly acetyl; C1 6alkyloxycarbonylC1 6alkyl or carboxyC1 6alkyloxy-C1 6alkyl, particularly carboxymethoxypropyl or carboxyethoxy-propyl; C1 6alkyl-carbonyloxyC1 6alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as 35 solubilizers are ,13-CD, 2,6-dimethyl-~-CD, randomly methylated ,B-cyclo-dextrin, 2-hydroxyethyl-~-CD, 2-hydroxyethyl-~-CD, 2-hydroxypropyl-~-CD and (2-carboxymethoxy)propyl-,13-CD, and in particular 2-hydroxypropyl-~-CD.
, CA 022280~4 1998-01-27 W O 97/15572 PCT~EP~6~'~16C&
The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.
The average molar substitution (M.S.) is used as a measure of the average number of s moles of alkoxy units per mole of anhydroglucose- The M-S-value can be deLc~n~illed by various analytical techniques such as nuclear m~n~tic resonance (NMR), mass s~c.,tlol~letry (MS) and infrared spectroscopy (IR)- Depending on the technique used, slightly ~lirrGl~,l t values may be obtained for one given cyclodextrin derivative. In the cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the lo present invention the M.S. as determined by mass spectrometry is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.~i. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
15 The average s~lbstitntion degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The D.S. value can be deL~ ed by various analytical techniques such as nuclear m~etic resonance (NMR), mass s~e-;LIo..lGLl~y (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin deliv~ e. In the cyclodextrin derivatives for use in the compositions according to the present invention the D.S. as deterrnined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values cleterrnined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
More particular ,B--and ~-cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially sllbstitutP~l cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of ~lirr~,.GnL
positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70%
for the 2 position and about 5% to 90% for the 6 position. Preferably the amount of unsubstituted ,~- or y-cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Another particularly interesting cyclodextrin derivative is randomly methylated ,B-cyclodextrin.
Most pl~fGIIGd cyclodextrin derivatives for use in the present invention are those 3s partially substituted ,B-cyclodextrin ethers or mixed ethers having hydroxypropyl~
hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) suhstitu~nts.
CA 022280~4 1998-01-27 W O 97~15572 PCT/EP9G/OS~C~
The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl-,B-cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted ,3-cyclodextrin. M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.
s ~' In order to minimi7e the risk of adverse reactions, an intravenous (or intraderrnal) formulation preferably contains as few ingredients as possible. Therefore, a formulation without a solubilizer such as a cyclodextrin is preferred. Further, the neuroprotectant solution (a) preferably does not contain a preservative. Oral liquid forrnulations on the other hand can co~ ise both a solubilizer such as a cyclodextrin and one or more preservatives.
In particular, the present invention relates to neuroprotectant solutions (a) comprising:
(i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 1 to 10% isotonizing agent;
(iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; and (iv) water q.s. ad 100%.
Preferably, the invention relates to neuroprotectant solutions (a) comprising:
(i) 0.01 to 1% lubeluzole N-oxide or a pharm~el-tic~lly acceptable addition salt or a solvate thereof;
(ii) 2 to 10% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and (iv) water q.s. ad 100%.
Most preferably, the invention relates to ne~lloprolectant solutions (a) co approximately:
(i) 0.05% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 5% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and (iv) water q.s. ad 100%.
The solutions (a) are sterilized using art-known techniques.
The neuroprotectant solution (a) of the present product is conveniently used in the tre~tm~n~ of patients suffering from acute hypoxia. In general it is contemplated that CA 022280~4 l998-0l-27 W O 97~15~72 PCTAEP~C~
an effective treatment for acute hypoxia involves arlmini~tering to the patient by infusion an amount of lubeluzole N-oxide in the range of 10 to 30 ml of solution (a) or from S to 15 mg of the active ingredient during the first hour of therapy. During the following 24 hours about 4/3 or 133% of that amount may be ~minict~red. That is,5 one starts with a relatively high initial flow which is then lowered considerably. The maintenance dose may be ~riminict~ored for several consecutive days.
crc.~bly about 15 ml of solution or about 7.5 mg of the active ingredient is ~cimini~t~red by infusion during the first hour of therapy, followed by about 20 ml of 0 solution or about lO mg of active ingredient during the next 24 hours. ~t is evident that said effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compound of the instant invention. The effective amount ranges mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.
The lubeluzole N-oxide solutions may conveniently be co-~r~mini~tered with a physiological salt solution following to art-known infusion procedures. They may also be accompanied by ~Aminictration of other anti-hypoxic drugs such as NMDA lcct;~lor 20 antagonists, e.g. aptiganel, eliprodil, selfotel, tirilazad or remacemide;
allLiLlllolllbolytiCs, e.g. tPA, streptokinase, staphylokinase, heparin or similar agents.
Since the product is meant to be ~-lminictered LIL~ellLly to patients suffering from hypoxia, for example in the ambulance, emergency room or intense care unit, an 25 infusion device or pack for the treatment of hypoxia comprising the product together with a disposable, independent drive unit is considered to be a most useful presentation of the product according to the present invention. As independent drive units for powering syringes, in particular prefilled syringes, there may be narned both gas-operated and vacuum-operated drive. An interesting gas-operated intraderrnal30 drug delivery device permitting delivery of a drug at a slow rate which can be precisely controlled is described in W0-95/13838, corresponding to US-5,527,288.The device comprises a housing with one or more drug reservoirs and a single hollow needl~e projecting outwards for a sufficient ~ t~n~ e so as to penetrate through the stratum corneum and epidermis into the dermis when the housing is pressed against 3s the skin. The device can be of modular design consisting of disposable cartridge units comprising the depletable components (active ingredient, power source) and a reusable drive ;unit comprising amongst others the housing and the electronic controls.
CA 022280~4 l998-0l-27 The present invention evidently also concerns the use of a product as described hereinbefore for the l,le~aldLion of a medicament for acute hypoxia treatment.
Similarly, the present invention relates to a method of treating patients suffering from hypoxia, comprising ~.lminict~oring to said patients a pharm~celltic~lly effective amount of an N-oxide product as described hereinbefore.
Experimental part F~m~?le 1 ~ a,alion of (-)-[cis] lubeluzole N-oxide hemihydrate.
To a stirred solution of lubeluzole (11.6 g; 27 mmol) in dichloromethane (700 ml), lo cooled to -10~C, was added m-chl~ oic acid (6-7 g; 31 mmol). The reaction ix.~ule was stirred for 24 hours, and then washed with an aqueous ammonia solution (2%; 3 times) and water (3 times). The organis phase was dried on MgSO4, filtered and evaporated, yielding 9.6 of raw material. The product (-)-[cis] lubeluzole N-oxide hemihydrate was purified by recryst~ tion from methylisopropylketone (mp. 182.8~C) (yield: 4.7 g; 38.7%) [~c]D =-8.73~ (1% in methanol) (comp. 1).
Fxample 2: Pharm~colo~ical exam~ple The useful anti-hypoxic ~lupellies of the product of the present invention can be demon~ lt;d in the following test procedure.
Post-Treatment in a Rat Photochemical Stroke Model.
Male Wistar rats, weighing 260-280 g, were anesthetized with halothane in a N2~/~2 mixture. The ~nim~l~ were placed in a stereotactic a~ld~us, the scalp was incised for exposure of the skull surface, and a catheter was inserted into a lateral tail vein. Rose 2s Bengal (30mg/lcg; 15 mg/ml in 0.9% NaCI) was infused intravenously for 2 minutes in ~nim~l.c with normal hemodynamics and blood gases. Thelt;afLel, the skull was focally illumin~ted with cold white light for 5 minutes by means of a fiber-optic bundle inside a l-mm diameter objective. The light was aimed at the hindlimb area of the rightparietal sensorimotor neocortex. Five minutes after infarct induction (i.e. 5 min after light offset), the rats are injected with either lubeluzole or lubeluzole N-oxide (comp. 1).
Neurologic tests, involving limb placing reactions, were concl~lcted on the first two days after infarction at 24-hour intervals after its induction. Tactile forward and sideways placing were tested by lightly contacting the table edge with the dorsal or lateral aspect of a paw (2 tests). Proprioceptive forward and sideways placing involved pushing the paw against the table edge in order to stim-llate limb muscles and joints (2 tests). Rats were also put along the edge of an elevated platform in order to assess CA 022280~4 l998-0l-27 W O 97/15572 PCT~EP9C/016C3 proprioceptive adduction: a paw was gently pulled down and away from the platform edge, and, upon sudden release, it was ~ çck~rl for retrieval and placing ( I test).
For each of the 5 tests, placing scores are: O, no placing; 1, incomplete and/or delayed placing; or 2, imm~ te~ complete placing. For each limb, the sllmm~
5 tactile/proprioceptive placing score, including the platform test, is maximally 10.
Results are reported from the deficient hinfllimh contralateral to the neocortical infarct.
Six rats are used for each dose.
compound placing score ... h-i........ ma~Li,llu", (median) lubeluzole 7.5 6 10 lubeluzole N-oxide 9.S 8 10 o From these results one can conclude that the test ~nim~l.c leceivi"g the lubeluzole N-oxide recover better from the ind~lced stroke than those receiving lubeluzole itself.
LUBELUZOLE N-OXIDE
s The present invention is concerned with neUI- pl(~te~ t N-oxide forms of lubeluzole, compositions cont~inin~ such N-oxide~s), methods of ~ alillg these and their use as a m.orlirinlo., in particular in the tre~tm~nt of conditions involving cerebral hypoxia.
In US~,861,785 there are described benzoxazol- and b~llzollliazolamine deli~ s having anti-hypoxic and anti-anoxic activity. In W0-92/14,73 1 some of these b~.lzotlliazolamine del;v~ti~es were disclosed having useful anti-stroke activity.
Injectable formulations of (S)~-[(2-benzothiazolyl) methylamino]-a-[(3,4-dinuol(J-phenoxy)methyl~-l-piperidine-ethan~l (generically known as lubeluzole) are disclosed in Eulope~- Patent application No. 94203422.4 filed 24 November 1994.
Conditions involving cerebral hypoxia con~lise stroke, more in particular icchaemic stroke, intracerebral h~PInorrh~e and subarachnoid haemorrhage, and head trauma.The l,e~.l.. nt of conditions involving cerebral hypoxia ~_ùl~ tly consists mainly of ne.~u~-ul~,clive and of haematologic therapeutic strategies. Optimal therapies remain 20 to be de terminP(l Such an optimized therapy for the tre~tm~nt of hypoxia is the subject of the present invention. In particular, it concerns providing an N-oxide of lubeluzole, a pharm~elltir~lly acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof, as a new medicine for the treatment of conditions involving cerebral hypoxia. The product is suitable for intravenous and intraderrnal 25 ~timinictration by infusion which is the most a~ u~.iate route of ~tlmini~tration for hypoxic patients, and also orally, which route is most suitable for m~int-on~ e therapy.
E~.p~.; . . .~ nt~ with the cis N-oxide form of lubeluzole in an animal model test of acute stroke in~ic~te that it has superior neuloproLeCtant activity over the compound lubeluzole.
The N-oxides of lubeluzole are meant to comprise those compounds wherein one or more of the nitrogen atoms are oxidized, in particular those wherein the piperidine nitrogen is oxidized.
3s More in particular, the present invention is concerned with lubeluzole N-oxide, the cis and trans forms of which are represented by the following formulae:
~ . , CA 022280~4 1998-01-27 W O 97/15572 PCT~EP96/04608 O~ 1~- ~ N ~ Icis,(S)]
OH
~ ~~~ ~ ~N ~ [~ans,(S)l Phann~ eut~ ly acceptable acid addition salts comprise the thel~eulically active, non-toxic salt forms obtained by treating a base form with an acid such as, for example, s an inorganic acid, e.g. hydrochloric, hydrobromic, sulfuric, nitric, phosphoric acid; or an organic acid, e.g. acetic, propanoic, hydroxyacetic, lactic, pyruvic, malonic, succinic, maleic, fumaric, tartaric, citric, meth~n~sulfonic, ethanesulfonic, ben7erlesll1fonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic acid.
Solvates of lubeluzole N-oxide are, for example hydrates, alcoholates.
The cis-oriented N-oxide of lubeluzole is particularly ~l~rcl.~d, and the most preferred form thereof is the hemihydrate, i.e. (-)-[cis] lubeluzole N-oxide hemihydrate.
The N-oxide(s) of lubeluzole can be prepared following art-known procedures of 5 preparing oxides of nitrogen-cont~ining products. They are conveniently prepared by dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant. Examples of such oxidants are hydrogen peroxide, peroxic acids, e.g.
m-chlor~,.benzoic acid, metal oxides, e.g. NaWO4 and the like. Suitable solventsare, for example, water and halogenated hydrocarbons, in particular dichloromethane.
Hereinafter, the amounts of each of the ingredients in liquid compositions are expressed as percentages by weight based on the total volume of the formulation,unless otherwise indicated. Amounts in solid preparations are expressed as percentages by weight based on the total weight of the forrnulation, unless otherwise indicated.
Pharmaceutical compositions of lubeluzole N-oxide suitable as medicaments according to the present invention comprise a pharmaceutically effective amount of active ingredient and one or more pharmaceutically acceptable excipients or carriers as known in the art. The pharmaceutical compositions are adapted for oral or parenteral -_ WO 97/15572 PCT/EI~C/O 1603 (including i~ cular, subcutaneous, intrade~mal and intravenous) ~lmini~tration.
The formulations are most conveniently presented in discrete dosage units. Generally, the pharmaceutically acceptable carrier for forrn~ tin~ the neuroprotectant lubeluzole N-oxide as an infusion is an aqueous solution (a) comprising water; an isotonizing 5 agent; and acid, base or buffer substances sufflcient to adjust the pH of the solution in the range of from 2.5 to 3.6.
In particular, the concentration of lubeluzole N-oxide in the present solutions (a) may range from 0.005% to 5%, ~lefe~ably from 0-01% to 1%, more preferably from 0.02%o to 0.2% and in particular is about 0.0~%.
Further, the present solutions (a) conveniently comprise from 1 to 10% isotonizing agent. The use of glucose as isotonizing agent has the advantage that very clearsolutions are obtained. Preferably, glucose is used in a concentration from 2 to 10%, 15 most preferably of about 5%.
The solutions (a) further comprise acid and base ~ubsl~lces to ~.A;nl~;n the pH of the solution in the range from 2.5 to 3.6, preferably in the range from 3.0 to 3.4, most preferably at about 3.2. Preferably, the pH of the solutions (a) is adjusted by 20 a~l~liate amounts of hydrochloric acid and sodium hydroxide. The pH may also be adjusted by buffer systems comprising mixtures o~ a~ riate amounts of an acid such as phosphoric, tartaric or citric acid, and a base, in particular sodium hydroxide.
In order to increase the solubility of lubeluzole N-oxide in the present formulations, a 25 solubilizer may be used. Conveniently, a cyclodextrin (CD) or a derivative thereof may be used. Appropriate cyclodextrin derivatives are a-, 13-. ~y-cyclodextrins or ethers and mixed ethers thereof wherein one or more of the hydroxy groups o~ the anhydroglucose units of the cyclodextrin are substituted with Cl 6alkyl, particularly methyl, ethyl or isopropyl, e.g. randomly methylated ¦3-cyclodextrin; hydroxy-30 C1 6alkyl, particularly hydroxyethyl, hydroxypropyl or hydroxy-butyl; carboxy-C1 6alkyl, particularly carboxymethyl or carboxyethyl; C1 6alkyl-carbonyl~
particularly acetyl; C1 6alkyloxycarbonylC1 6alkyl or carboxyC1 6alkyloxy-C1 6alkyl, particularly carboxymethoxypropyl or carboxyethoxy-propyl; C1 6alkyl-carbonyloxyC1 6alkyl, particularly 2-acetyloxypropyl. Especially noteworthy as 35 solubilizers are ,13-CD, 2,6-dimethyl-~-CD, randomly methylated ,B-cyclo-dextrin, 2-hydroxyethyl-~-CD, 2-hydroxyethyl-~-CD, 2-hydroxypropyl-~-CD and (2-carboxymethoxy)propyl-,13-CD, and in particular 2-hydroxypropyl-~-CD.
, CA 022280~4 1998-01-27 W O 97/15572 PCT~EP~6~'~16C&
The term mixed ether denotes cyclodextrin derivatives wherein at least two cyclodextrin hydroxy groups are etherified with different groups such as, for example, hydroxypropyl and hydroxyethyl.
The average molar substitution (M.S.) is used as a measure of the average number of s moles of alkoxy units per mole of anhydroglucose- The M-S-value can be deLc~n~illed by various analytical techniques such as nuclear m~n~tic resonance (NMR), mass s~c.,tlol~letry (MS) and infrared spectroscopy (IR)- Depending on the technique used, slightly ~lirrGl~,l t values may be obtained for one given cyclodextrin derivative. In the cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the lo present invention the M.S. as determined by mass spectrometry is in the range of 0.125 to 10, in particular of 0.3 to 3, or from 0.3 to 1.5. Preferably the M.~i. ranges from about 0.3 to about 0.8, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. M.S. values determined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
15 The average s~lbstitntion degree (D.S.) refers to the average number of substituted hydroxyls per anhydroglucose unit. The D.S. value can be deL~ ed by various analytical techniques such as nuclear m~etic resonance (NMR), mass s~e-;LIo..lGLl~y (MS) and infrared spectroscopy (IR). Depending on the technique used, slightly different values may be obtained for one given cyclodextrin deliv~ e. In the cyclodextrin derivatives for use in the compositions according to the present invention the D.S. as deterrnined by MS is in the range of 0.125 to 3, in particular of 0.2 to 2 or from 0.2 to 1.5. Preferably the D.S. ranges from about 0.2 to about 0.7, in particular from about 0.35 to about 0.5 and most particularly is about 0.4. D.S. values cleterrnined by NMR or IR preferably range from 0.3 to 1, in particular from 0.55 to 0.75.
More particular ,B--and ~-cyclodextrin hydroxyalkyl derivatives for use in the compositions according to the present invention are partially sllbstitutP~l cyclodextrin derivatives wherein the average degree of alkylation at hydroxyl groups of ~lirr~,.GnL
positions of the anhydroglucose units is about 0% to 20% for the 3 position, 2% to 70%
for the 2 position and about 5% to 90% for the 6 position. Preferably the amount of unsubstituted ,~- or y-cyclodextrin is less than 5% of the total cyclodextrin content and in particular is less than 1.5%. Another particularly interesting cyclodextrin derivative is randomly methylated ,B-cyclodextrin.
Most pl~fGIIGd cyclodextrin derivatives for use in the present invention are those 3s partially substituted ,B-cyclodextrin ethers or mixed ethers having hydroxypropyl~
hydroxyethyl and in particular 2-hydroxypropyl and/or 2-(1-hydroxypropyl) suhstitu~nts.
CA 022280~4 1998-01-27 W O 97~15572 PCT/EP9G/OS~C~
The most preferred cyclodextrin derivative for use in the compositions of the present invention is hydroxypropyl-,B-cyclodextrin having a M.S. in the range of from 0.35 to 0.50 and containing less than 1.5% unsubstituted ,3-cyclodextrin. M.S. values determined by NMR or IR preferably range from 0.55 to 0.75.
s ~' In order to minimi7e the risk of adverse reactions, an intravenous (or intraderrnal) formulation preferably contains as few ingredients as possible. Therefore, a formulation without a solubilizer such as a cyclodextrin is preferred. Further, the neuroprotectant solution (a) preferably does not contain a preservative. Oral liquid forrnulations on the other hand can co~ ise both a solubilizer such as a cyclodextrin and one or more preservatives.
In particular, the present invention relates to neuroprotectant solutions (a) comprising:
(i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 1 to 10% isotonizing agent;
(iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; and (iv) water q.s. ad 100%.
Preferably, the invention relates to neuroprotectant solutions (a) comprising:
(i) 0.01 to 1% lubeluzole N-oxide or a pharm~el-tic~lly acceptable addition salt or a solvate thereof;
(ii) 2 to 10% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and (iv) water q.s. ad 100%.
Most preferably, the invention relates to ne~lloprolectant solutions (a) co approximately:
(i) 0.05% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 5% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and (iv) water q.s. ad 100%.
The solutions (a) are sterilized using art-known techniques.
The neuroprotectant solution (a) of the present product is conveniently used in the tre~tm~n~ of patients suffering from acute hypoxia. In general it is contemplated that CA 022280~4 l998-0l-27 W O 97~15~72 PCTAEP~C~
an effective treatment for acute hypoxia involves arlmini~tering to the patient by infusion an amount of lubeluzole N-oxide in the range of 10 to 30 ml of solution (a) or from S to 15 mg of the active ingredient during the first hour of therapy. During the following 24 hours about 4/3 or 133% of that amount may be ~minict~red. That is,5 one starts with a relatively high initial flow which is then lowered considerably. The maintenance dose may be ~riminict~ored for several consecutive days.
crc.~bly about 15 ml of solution or about 7.5 mg of the active ingredient is ~cimini~t~red by infusion during the first hour of therapy, followed by about 20 ml of 0 solution or about lO mg of active ingredient during the next 24 hours. ~t is evident that said effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compound of the instant invention. The effective amount ranges mentioned hereinabove are therefore guidelines only and are not intended to limit the scope or use of the invention to any extent.
The lubeluzole N-oxide solutions may conveniently be co-~r~mini~tered with a physiological salt solution following to art-known infusion procedures. They may also be accompanied by ~Aminictration of other anti-hypoxic drugs such as NMDA lcct;~lor 20 antagonists, e.g. aptiganel, eliprodil, selfotel, tirilazad or remacemide;
allLiLlllolllbolytiCs, e.g. tPA, streptokinase, staphylokinase, heparin or similar agents.
Since the product is meant to be ~-lminictered LIL~ellLly to patients suffering from hypoxia, for example in the ambulance, emergency room or intense care unit, an 25 infusion device or pack for the treatment of hypoxia comprising the product together with a disposable, independent drive unit is considered to be a most useful presentation of the product according to the present invention. As independent drive units for powering syringes, in particular prefilled syringes, there may be narned both gas-operated and vacuum-operated drive. An interesting gas-operated intraderrnal30 drug delivery device permitting delivery of a drug at a slow rate which can be precisely controlled is described in W0-95/13838, corresponding to US-5,527,288.The device comprises a housing with one or more drug reservoirs and a single hollow needl~e projecting outwards for a sufficient ~ t~n~ e so as to penetrate through the stratum corneum and epidermis into the dermis when the housing is pressed against 3s the skin. The device can be of modular design consisting of disposable cartridge units comprising the depletable components (active ingredient, power source) and a reusable drive ;unit comprising amongst others the housing and the electronic controls.
CA 022280~4 l998-0l-27 The present invention evidently also concerns the use of a product as described hereinbefore for the l,le~aldLion of a medicament for acute hypoxia treatment.
Similarly, the present invention relates to a method of treating patients suffering from hypoxia, comprising ~.lminict~oring to said patients a pharm~celltic~lly effective amount of an N-oxide product as described hereinbefore.
Experimental part F~m~?le 1 ~ a,alion of (-)-[cis] lubeluzole N-oxide hemihydrate.
To a stirred solution of lubeluzole (11.6 g; 27 mmol) in dichloromethane (700 ml), lo cooled to -10~C, was added m-chl~ oic acid (6-7 g; 31 mmol). The reaction ix.~ule was stirred for 24 hours, and then washed with an aqueous ammonia solution (2%; 3 times) and water (3 times). The organis phase was dried on MgSO4, filtered and evaporated, yielding 9.6 of raw material. The product (-)-[cis] lubeluzole N-oxide hemihydrate was purified by recryst~ tion from methylisopropylketone (mp. 182.8~C) (yield: 4.7 g; 38.7%) [~c]D =-8.73~ (1% in methanol) (comp. 1).
Fxample 2: Pharm~colo~ical exam~ple The useful anti-hypoxic ~lupellies of the product of the present invention can be demon~ lt;d in the following test procedure.
Post-Treatment in a Rat Photochemical Stroke Model.
Male Wistar rats, weighing 260-280 g, were anesthetized with halothane in a N2~/~2 mixture. The ~nim~l~ were placed in a stereotactic a~ld~us, the scalp was incised for exposure of the skull surface, and a catheter was inserted into a lateral tail vein. Rose 2s Bengal (30mg/lcg; 15 mg/ml in 0.9% NaCI) was infused intravenously for 2 minutes in ~nim~l.c with normal hemodynamics and blood gases. Thelt;afLel, the skull was focally illumin~ted with cold white light for 5 minutes by means of a fiber-optic bundle inside a l-mm diameter objective. The light was aimed at the hindlimb area of the rightparietal sensorimotor neocortex. Five minutes after infarct induction (i.e. 5 min after light offset), the rats are injected with either lubeluzole or lubeluzole N-oxide (comp. 1).
Neurologic tests, involving limb placing reactions, were concl~lcted on the first two days after infarction at 24-hour intervals after its induction. Tactile forward and sideways placing were tested by lightly contacting the table edge with the dorsal or lateral aspect of a paw (2 tests). Proprioceptive forward and sideways placing involved pushing the paw against the table edge in order to stim-llate limb muscles and joints (2 tests). Rats were also put along the edge of an elevated platform in order to assess CA 022280~4 l998-0l-27 W O 97/15572 PCT~EP9C/016C3 proprioceptive adduction: a paw was gently pulled down and away from the platform edge, and, upon sudden release, it was ~ çck~rl for retrieval and placing ( I test).
For each of the 5 tests, placing scores are: O, no placing; 1, incomplete and/or delayed placing; or 2, imm~ te~ complete placing. For each limb, the sllmm~
5 tactile/proprioceptive placing score, including the platform test, is maximally 10.
Results are reported from the deficient hinfllimh contralateral to the neocortical infarct.
Six rats are used for each dose.
compound placing score ... h-i........ ma~Li,llu", (median) lubeluzole 7.5 6 10 lubeluzole N-oxide 9.S 8 10 o From these results one can conclude that the test ~nim~l.c leceivi"g the lubeluzole N-oxide recover better from the ind~lced stroke than those receiving lubeluzole itself.
Claims (20)
1. An N-oxide form of lubeluzole, a pharmaceutically acceptable acid addition salt form, a solvate or a stereochemically isomeric form thereof.
2. An N-oxide according to claim 1 wherein the piperidine nitrogen is oxidized.
3. An N-oxide according to claim 2 wherein the cis and trans forms are represented by the formulae:
4. An N-oxide according to claim 1 wherein the compound is (-)-[cis] lubeluzole N-oxide hemihydrate.
5. A process of preparing an N-oxide of lubeluzole comprising the steps of dissolving lubeluzole in a solvent and adding thereto a sufficient amount of a suitable oxidant.
6. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
7. A composition according to claim 6 adapted for oral or parenteral administration.
8. A composition according to claim 7 wherein the N-oxide is formulated in an aqueous solution comprising water; an isotonizing agent; and acid, base or buffer substances sufficient to adjust the pH of the solution in the range of from 2.5 to 3.6.
9. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises:
(i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 1 to 10% isotonizing agent;
(iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; an (iv) water q.s. ad 100%.
(i) 0.005 to 5% lubeluzole N-oxide or a pharmaceutically acceptable addition salt or a solvate thereof;
(ii) 1 to 10% isotonizing agent;
(iii) acid and/or base substances to adjust the pH in the range from 2.5 to 3.6; an (iv) water q.s. ad 100%.
10. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises:
(i) 0.01 to 1% lubeluzole N-oxide or a pharmaceutically acceptable addition saltor a solvate thereof;
(ii) 2 to 10% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and (iv) water q.s. ad 100%.
(i) 0.01 to 1% lubeluzole N-oxide or a pharmaceutically acceptable addition saltor a solvate thereof;
(ii) 2 to 10% glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH in the range from 3.0 to 3.4; and (iv) water q.s. ad 100%.
11. A composition according to claim 8 wherein the neuroprotectant solution (a) comprises:
(i) 0.05 % (w/v) lubeluzole N-oxide or a pharmaceutically acceptable acid addition salt or a solvate thereof;
(ii) 5 % (w/v) glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and (iv) water q.s. ad 100 %.
(i) 0.05 % (w/v) lubeluzole N-oxide or a pharmaceutically acceptable acid addition salt or a solvate thereof;
(ii) 5 % (w/v) glucose;
(iii) hydrochloric acid and sodium hydroxide to adjust the pH to about 3.2; and (iv) water q.s. ad 100 %.
12. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of from 10 to 30 ml, and comprises about 5 to 15 mg lubeluzole N-oxide.
13. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of about 15 ml, and comprises about 7.5 mg lubeluzole N-oxide.
14. A composition according to claim 8 wherein the neuroprotectant solution (a) is present in an amount of about 20 ml, and comprises about 10 mg lubeluzole N-oxide.
15. An infusion device or pack for the treatment of stroke comprising an N-oxideproduct according to any one of claims 1 to 4, with a disposable, independent drive unit.
16. An infusion pack according to claim 15 wherein the independent drive unit is gas-operated or vacuum-operated.
17. A product as claimed in any one of claims 1 to 4 for use as a medicine.
18. A product as claimed in claim 17 for use in the treatment of conditions involving cerebral hypoxia.
19. A product as claimed in claim 17 for use in the treatment of stroke and head trauma.
20. A product as claimed in claim 17 for use in the treatment of ischaemic stroke, intracerebral haemorrhage and subarachnoidal haemorrhage.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP95202887 | 1995-10-25 | ||
| EP95202887.6 | 1996-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2228054A1 true CA2228054A1 (en) | 1997-05-01 |
Family
ID=8220766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002228054A Abandoned CA2228054A1 (en) | 1995-10-25 | 1996-10-21 | Lubeluzole n-oxide |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0843674A1 (en) |
| JP (1) | JPH11513699A (en) |
| CN (1) | CN1200122A (en) |
| AU (1) | AU7298296A (en) |
| CA (1) | CA2228054A1 (en) |
| IL (1) | IL123083A0 (en) |
| NO (1) | NO981687D0 (en) |
| WO (1) | WO1997015572A1 (en) |
| ZA (2) | ZA968952B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US7544500B2 (en) | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
| PT2403865E (en) | 2009-03-03 | 2015-11-18 | Grifols Therapeutics Inc | Methods for preparing plasminogen |
| US10100239B2 (en) | 2013-01-23 | 2018-10-16 | Adeka Corporation | Antistatic agent, antistatic agent composition, antistatic resin composition, and molded body |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4306069A (en) * | 1980-06-19 | 1981-12-15 | Mead Johnson & Company | Encainide N-oxide |
| CA1260474A (en) * | 1984-12-03 | 1989-09-26 | Raymond A. Stokbroekx | Benzoxazol- and benzothiazolamine derivatives |
| ZW1992A1 (en) * | 1991-02-25 | 1993-09-22 | Janssen Pharmaceutica Nv | 4-/(2-benzotiazolyl)methylamino/-b-/(3,4-difluorephenoxy)methyl/-1-piperidine ethanol |
-
1996
- 1996-10-21 CN CN96197774A patent/CN1200122A/en active Pending
- 1996-10-21 CA CA002228054A patent/CA2228054A1/en not_active Abandoned
- 1996-10-21 IL IL12308396A patent/IL123083A0/en unknown
- 1996-10-21 JP JP9516279A patent/JPH11513699A/en active Pending
- 1996-10-21 AU AU72982/96A patent/AU7298296A/en not_active Abandoned
- 1996-10-21 EP EP96934801A patent/EP0843674A1/en not_active Withdrawn
- 1996-10-21 WO PCT/EP1996/004608 patent/WO1997015572A1/en not_active Application Discontinuation
- 1996-10-24 ZA ZA9608952A patent/ZA968952B/en unknown
- 1996-10-24 ZA ZA9608961A patent/ZA968961B/en unknown
-
1998
- 1998-04-15 NO NO981687A patent/NO981687D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA968952B (en) | 1998-04-24 |
| NO981687L (en) | 1998-04-15 |
| NO981687D0 (en) | 1998-04-15 |
| IL123083A0 (en) | 1998-09-24 |
| MX9803272A (en) | 1998-09-30 |
| AU7298296A (en) | 1997-05-15 |
| EP0843674A1 (en) | 1998-05-27 |
| WO1997015572A1 (en) | 1997-05-01 |
| JPH11513699A (en) | 1999-11-24 |
| ZA968961B (en) | 1998-04-24 |
| CN1200122A (en) | 1998-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100643553B1 (en) | A pharmaceutical compositions to enhance white blood cell count | |
| JP6407221B2 (en) | Antibacterial composition | |
| US20130189218A1 (en) | Pharmaceutical formulations for fumagillin derivative-phf conjugates | |
| CN105061358A (en) | Crystalline methylthioninium chloride hydrates | |
| CN110354270B (en) | Artesunate polyethylene glycol derivative and preparation method and application thereof | |
| JP2009535410A (en) | Pyrroloquinoline quinone and use thereof | |
| CA2228054A1 (en) | Lubeluzole n-oxide | |
| JPH11507081A (en) | Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents | |
| RU2531350C2 (en) | Compound, possessing detrusor-contracting and urethral sphincter-relaxing activity | |
| US6340696B1 (en) | Viral treatment | |
| CN112209834B (en) | Organic nitrite donor and preparation method and medical application thereof | |
| EP0862434A1 (en) | Infusions of neuroprotectants and perfluorochemicals | |
| JP2961093B2 (en) | Stable and long-acting salts of carboxamide for the treatment of joint diseases | |
| JPH11515010A (en) | Injection of neuroprotective and thrombolytic agents | |
| JPH0381219A (en) | Remedy for gastric mucosal disorder | |
| JPH06502155A (en) | How to treat demyelinating diseases | |
| EP1161243A2 (en) | Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin | |
| JP2009539879A (en) | Indenoisoquinoline-releasing polymer composite | |
| CN114409610A (en) | Oxadiazole derivatives, their preparation and use | |
| TW202339711A (en) | Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids | |
| KR100454649B1 (en) | Seleno Compounds Containing Nitrone Moiety, Their Preparation and Their Therapeutic Uses | |
| JP2008509141A (en) | Methods and compositions for reducing tissue irritation in parenteral formulations | |
| CN115300511A (en) | Medical application of composition | |
| KR100454647B1 (en) | Dialkylhydroxybenzoic Acid Derivatives Containing Metal Chelating Groups and Their Therapeutic Uses | |
| WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |